Elevance Health is acquiring Paragon Infusion for “well north of $1 billion,” three sources tell Axios’ Claire Rychlewski.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELV:
- Elevance, HCSC vying for Cigna’s Medicare Advantage unit, Bloomberg says
- Elevance, HCSC vying for Cigna Medicare Advantage unit, Bloomberg says
- Elevance Health price target lowered by $40 at BofA, here’s why
- Elevance Health price target lowered to $552 from $569 at JPMorgan
- Cigna price target raised to $351 from $345 at Deutsche Bank
